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Abstract:
The design and analysis of active-control trials to evaluate experimental HIV pre-exposure prophylaxis (PrEP)
agents pose serious statistical challenges. We recently proposed a new outcomemeasure, the averted infections
ratio (AIR) – the proportion of infections that would be averted by using the experimental agent rather than the
control agent (compared to no intervention). The main aim of the current paper is to examine the mathematical
connection between AIR and the HIV incidence rate ratio, the standard outcome measure. We also consider
the sample size implications of the choice of primary outcome measure and explore the connection between
effectiveness and efficacy under a simplified model of adherence.
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1 Introduction
Late-phase trials of experimental HIV pre-exposure prophylaxis (PrEP) agents are currently designed as active-
control trials, with oral TDF-FTC, currently the only drug licensed for this indication, constituting the control
regimen. In the absence of a validated surrogate, the primary endpoint is an incidentHIV infection (Cutrell et al.
2017; Janes et al. 2019). The standard primary outcomemeasure, following the approach used in earlier placebo
controlled trials, is the HIV incidence rate ratio comparing the experimental and control groups (Cutrell et al.
2017; Donnell et al. 2013). In a recent paper, we pointed out serious difficulties in the interpretation of this
measure and described an alternative measure of effectiveness, the averted infections ratio (AIR), based on the
concept of averted infections (Dunn et al. 2018). The AIR is interpreted as proportion of infections that would
be averted by using the experimental agent rather than the control agent (compared to no intervention). The
measure is simple to interpret, has direct clinical and public health relevance, and is a natural preservation-of-
effect metric for assessing statistical non-inferiority.
The main aim of this paper is to examine the connection between AIR and the rate ratio in more mathemat-
ical detail, and to explain how the AIR allows a reduction in sample size for the same level of statistical power.
We also point out a curious feature of the AIR concerning effectiveness and efficacy under a simplified model
of adherence.
2 Statistical Formulation
Currently, most studies of experimental PrEP agents are designed as non-inferiority trials, where the primary
aim is to show that HIV incidence is not unacceptably higher with the experimental agent than with TDF-
FTC. This is formally judged by whether the observed confidence limit (lower or upper, as appropriate) for the
primary outcome measure exceeds a pre-defined non-inferiority margin. A “preservation of effect” argument
is often used as a basis for this margin i. e. to aim to show that the experimental agent preserves a minimum
fraction of the effect of TDF-FTC relative to placebo or no treatment (Snapinn and Jiang 2008).
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Denote the experimental and control groups by the subscripts E and C, respectively. We also consider a
hypothetical placebo group denoted by the subscript P. Let λ (subscripted by E, C, or P) denote the population-
average HIV incidence rate (used interchangeably for both the parameter and the estimator), and let Δ denote
the non-inferiority margin.
The standard analytical approach considers inference on a log incidence scale, the “natural” parameteri-
sation for the exponential family of distributions (Nelder 1998). Non-inferiority is demonstrated if it is shown
(probabilistically) that
log (𝜆E) − log (𝜆C) < (1− Δ) [log (𝜆P) − log (𝜆C)] (1)
⇒ log (𝜆P) − log (𝜆E)log (𝜆P) − log (𝜆C)
> Δ (2)
Denote the expression on the LHS of eq. (2) as STD (shorthand for Standard). Although this formulation is not
conventional, it facilitates a comparison with the AIR. The latter is defined by (Dunn et al. 2018):
AIR = 𝜆P − 𝜆E𝜆P − 𝜆C
(3)
The superficial similarity of eqs. (2) and (3) masks a key difference: AIR is essentially a (standardised) rate
difference measure and STD essentially a (standardised) rate ratio measure.
Specifying 𝜆P, the incidence rate that would have been observed in the absence of an intervention, is often
not practicable. Another tack is to make inferences via the assumed effectiveness of the control group agent:
𝜃C = 1 − 𝜆C/𝜆P (4)
Re-arranging eq. (4) and substituting in eqs. (2) and (3), STD can be expressed as
STD = 1− log (𝜆C/𝜆E)log (1− 𝜃C)
(5)
and AIR expressed as
AIR = 1− 𝜆E/𝜆C (1− 𝜃C)𝜃C
(6)
Eq. (6) reveals an interesting point. Although AIR was formulated as a rate difference based measure, when
estimated via 𝜃C it becomes a linear function of the rate ratio (experimental group relative to control group)
observed in the trial. The remainder of this paper considers inference based on 𝜃C rather than 𝜆P. Also, from
this perspective, there is no need to conceptualise constant incidence rates as implied by eqs. (2), (3), and (4).
The only underlying assumption is a constant hazard ratio, which can be estimated by Cox regression models
with no or little loss in statistical efficiency (Efron 1977).
3 Comparison ofAIR andSTD
We exemplify the difference between AIR and STD using a hypothetical two-arm active-control trial. The fol-
lowing conditions are fixed: (a) equal follow-up in the control and experimental arms (b) 40 HIV endpoints in
control arm (c) control agent effectiveness of 60 % (relative to placebo). The number of HIV endpoints in the
experimental arm is allowed to vary between 20 and 70 (rate ratio of 0.50 to 1.75).
Figure 1 shows the relationship between AIR and STD and the number of HIV endpoints in experimental
arm. Both AIR and STD are equal to onewhen 40HIV endpoints are also observed in the experimental arm (i. e.
the two agents are equally effective). Both measures are greater than 1 when there are fewer than 40 endpoints
in the experimental arm (i. e. it is more effective than the control agent) although the AIR is less than STD.
Conversely, the AIR is greater than STD when there are more than 40 endpoints in the experimental arm (i. e.
it is less effective than the control agent).
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Figure 1: Comparison of point estimates and lower 5 % confidence limit for AIR and STD estimators. Analysis based on a
hypothetical two-arm active-control trial (details specified in Section 3).
The lower confidence limits, upon which the assessment of non-inferiority is based, are more pertinent than
the point estimates. The lower 5 % confidence limits are represented by dotted lines in Figure 1, along with a
grey horizontal line representing a non-inferiority margin of 50 %. Focussing on where these lines intercept,
non-inferiority is seen to be demonstrated by AIR if there are 49 or fewer HIV endpoints, and by STD if there
are 44 or fewer HIV endpoints. That is, if between 45 and 49 HIV endpoints are observed then non-inferiority
is demonstrated by AIR but not by STD. This implies that greater statistical power can be achieved by using the
AIR rather than the rate ratio. The following section looks at this algebraically.
4 Implications for Sample Size byUsing theAIRRather thanRateRatio
From eq. (5), non-inferiority is demonstrated by the rate ratio if the upper confidence limit for log (𝜆E/𝜆C ) is
less than (Δ− 1) log (1− 𝜃C). Similarly from eq. (6), non-inferiority is demonstrated by the AIR if the upper
confidence limit for log (𝜆E/𝜆C ) is less than log (1− 𝜃CΔ) − log (1− 𝜃C). It could be questioned whether it is
valid to use the same value of Δ for two different metrics but it is not obvious why one should demand a higher
or lower preservation of effect with one metric than the other.
As inference regarding non-inferiority is based on log (𝜆E/𝜆C ) in both cases, the two approaches differ only
in terms of the non-inferiority margin (on the rate ratio scale). Under the standard statistical approach, the
approximate sample size to demonstrate non-inferiority, for a specified power and confidence interval (and
assuming a 1:1 allocation ratio), can be shown to be inversely proportional to (Zhu 2016):
[ (Δ− 1) log (1− 𝜃C ) − log (𝜆E/𝜆C) ]2 (7)
Similarly, under the AIR approach, the approximate sample size is inversely proportional to
[log (1− 𝜃CΔ) − log (1− 𝜃C) − log (𝜆E/𝜆C) ]2 (8)
Thus the ratio of sample sizes (more precisely, the required person-years follow-up) under the standard statis-
tical approach compared with AIR is given by:
[ log
(1− 𝜃CΔ) − log (1− 𝜃C) − log (𝜆E/𝜆C)
(Δ− 1) log (1− 𝜃C ) − log (𝜆E/𝜆C)
]
2
(9)
In some studies (e. g. HPTN-083 trial comparing injectable cabotegravir versus oral TDF-FTC) the experimental
agent is assumed to be more effective than the control agent for the purposes of sample size calculation. How-
ever, power is often evaluated (e. g. DISCOVER trial comparing oral TAF-FTC versus oral TDF-FTC) assuming
the experimental and control agents are equally effective (𝜆E/𝜆C = 1). In this case eq. (9) simplifies to
[ log
(1− 𝜃CΔ) − log (1− 𝜃C)
(Δ− 1) log (1− 𝜃C )
]
2
(10)
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Figure 2 shows the percentage reduction in sample size (a simple transformation of the ratio) plotted against 𝜃C
in the range 0.5–0.8, for Δ = 0.5 (the commonly accepted value for the non-inferioritymargin).When 𝜆E/𝜆C = 1,
the reduction ranges between 27 % (𝜃C = 0.5) and 46 % (𝜃C = 0.8). The degree of advantage by using the
AIR is diminished when 𝜆E/𝜆C < 1. For example, when 𝜆E/𝜆C = 0.7, the reduction ranges between 15 %
(𝜃C = 0.5) and 36 % (𝜃C = 0.8). It is emphasised that these are assumed values for 𝜆E/𝜆Cwhich pertain to
the sample size calculation. The actual gain in power by using the AIR depends on the true value of 𝜆E/𝜆C ,
which becomes apparent only once the trial is conducted. We note from eq. (9) that the relative sample sizes are
independent of 𝜆P, the underlying HIV incidence rate in the study population, although the absolute sample
sizes are dependent on this parameter.
Figure 2: Percentage reduction in sample size achieved by using AIR rather than rate ratio as primary effect measure, ac-
cording to control drug effectiveness and rate ratio (experimental to control arms). All input parameters assumed equal.
Non-inferiority margin (Δ) = 0.5.
5 Efﬁcacy andEffectiveness
There is a key distinction between efficacy and effectiveness (Sommer and Zeger 1991; Dai et al. 2013; Wilder-
Smith et al. 2017). Efficacy, the measure of key interest to regulators, is the effect of the intervention under ide-
alised conditions, including taking the drug precisely as prescribed. Effectiveness, of more relevance to public
health decisionmakers, is the effect of the intervention in real-life clinical practice, allowing for imperfect adher-
ence. Our paper thus far has implicitly referred to effectiveness (θ); in this section, we consider the relationship
between effectiveness and efficacy for the different effect measures.
For simplicity, we assume that effectiveness is a function of efficacy and adherence only. A meaningful
definition of adherence is not straightforward, particularly for “on demand” regimens, since the presence of
drug during periods without risky sex is irrelevant (Molina et al. 2015). Again simplifying, in a binary manner,
we consider that for each sex act involving exposure to HIV there is: (a) a probability P that there are protective
PrEP concentrations, which multiply the risk of acquiring infection by a factor (1- ψ) (b) a probability (1-P)
that PrEP concentrations are wholly inadequate and confer zero protection against infection. By definition, ψ
denotes PrEP efficacy. Our approach has parallels with that of Dai et al. who also invoke a binary division in
a counterfactual framework, but splitting participants (rather than sex acts) into compliers and non-compliers
(Dai et al. 2013). In a more empirical approach, Hanscom et al. define adherence as the proportion of active-
arm participants with detectable levels of PrEP (Hanscom et al. 2018). More realistic, but less tractable, models
would allow the level of protection to be a continuous function of PrEP drug concentrations (Anderson et al.
2012).
In our framework, again using the subscripts E, C, and P to denote the experimental, control, and hypothet-
ical placebo groups:
𝜆C = (1− PC) 𝜆P + PC (1− 𝜓C) 𝜆P = 𝜆P (1− PC 𝜓C ) (11)
𝜆E = (1− PE) 𝜆P + PE (1− 𝜓E) 𝜆P = 𝜆P (1− PE 𝜓E) (12)
In terms of effectiveness,
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𝜃C = 1−
𝜆C
𝜆P
= 1− 𝜆P (1− PC 𝜓C)𝜆P
= PC 𝜓C
and similarly for 𝜃E.
Manipulating eq. (3),
AIR = PE 𝜓EPC 𝜓C
= 𝜃E𝜃C
(13)
As we pointed out previously, the AIR can be expressed as the effectiveness of the experimental agent divided
by the effectiveness of the active-control agent (Dunn et al. 2018). Surprisingly, it also equal to the ratio of the
respective efficacies if PE = PC. Thus if adherence is the same for the two agents being compared (which may
well be the case for trials evaluating similar oral formulations, such as the DISCOVER trial), the AIR can be
interpreted in terms of either effectiveness or efficacy, regardless of the level of adherence in the trial. This
does not mean that the level of adherence achieved is irrelevant, however, since this affects the precision of the
estimate (higher adherence, more precision).
In contrast both the rate ratio and rate difference depend on the level of adherence, even if this is equal
between the two groups.
𝜆E/𝜆C =
1− PE 𝜓E
1− PC 𝜓C
; 𝜆E − 𝜆C = 𝜆P (PC 𝜓C − PE 𝜓E) (14)
These measures are drawn closer to the null values of one and zero, respectively, the higher the level of non-
adherence. Figure 3 shows how the various measures relate to adherence (as quantified by the parameter P
described above) when 𝜃C = 0.8, 𝜃E = 0.6, and 𝜆P = 0.05. As predicted by the algebra, the value of AIR is invari-
ant.
Figure 3: Point estimates of AIR, rate ratio, and rate difference as a function of adherence under a simplified model (see
Section 5). Adherence represents the probability of protective PrEP concentrations during each sex act involving expo-
sure to HIV. Footnote. Assumptions: control drug effectiveness = 80 %, experimental drug effectiveness = 60 %, placebo
incidence = 5 per 100 PY.
6 Discussion
In this short note we provide more mathematical detail about the AIR than we presented in our original expo-
sition (Dunn et al. 2018). Apart from ease of interpretation, its adoption allows the use of smaller sample sizes
comparedwith basing inference on the rate ratio. These savings are substantial, typically between 30 %and 40 %
for plausible assumptions about the effectiveness of the active control agent. The reduction in sample size may
seem like statistical sleight-of-hand,merely being a consequence of using a less stringent non-inferioritymargin
for the rate ratio. Our counter-argument is that the AIR is a more meaningful scale for assessing preservation of
effect. Work in progress on sample size calculations based on the hypothetical placebo incidence (rather than
the effectiveness of the control agent) suggests an even greater advantage in using the AIR.
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Another interpretational advantage of the AIR is that it reflects preservation of effect for both effectiveness
and efficacy for two agents with the same adherence. We stress that this interpretation only applies under our
postulated model, which includes simplistic assumptions. Further research is required to test the robustness of
this conclusion under different model formulations. Irrespective of the intended analytical approach, there are
compelling reasons to attempt to measure adherence within a trial, including generating knowledge to allow
development of more realistic causal models and to examine the plausibility of prior assumptions about the
effectiveness of the control agent (Dai et al. 2013; Hanscom et al. 2018).
Finally, although the AIR was developed in the context of non-inferiority trials, this does not preclude its
application to superiority trials. Indeed, we would argue that it offers the same interpretational advantages
over the rate ratio in this setting as well. The gains in statistical power will also hold given that the problems
of sample size calculation for non-inferiority and superiority trials are essentially symmetrical (Dunn, Copas,
and Brocklehurst 2018).
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